How well can you predict the outcome of clinical trials? Not as well as you may think

Researchers might not be as great at determining the likelihood of a clinical trial’s success as they think they are.

If researchers were better at forecasting the results of clinical trials — and, say, could avoid having to run trials that will inevitably fail — more resources could be devoted to trials that might succeed.

But, it turns out, researchers might not be great at determining the likelihood of a trial’s success.

In unpublished research, McGill bioethicist Jonathan Kimmelman and colleagues asked cancer experts to forecast the probability of more than a dozen clinical trials hitting their primary endpoint. They found that the predictions overall were not very accurate, and, if anything, were too pessimistic.

Kimmelman presented his research last week at Harvard Medical School and spoke to STAT afterward about the importance of forecasting in clinical trials.

You're reading a preview, sign up to read more.

More from STAT

STAT2 min read
This Troubled Biotech Needed Cash, So It Turned To A Predatory Lender: Its Own CEO
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting r
STAT7 min readPolitics
Trump Has Made A Priority Of Trying To Lower Drug Prices. But Many Of His Most Ardent Supporters Don’t Know It
Few of his supporters — even those willing to blast "Big Pharma" or whose ears perked up at the mention of drug importation — had any idea that Trump had…
STAT4 min readSociety
AIDS Activists Say Gilead Put Profits Over Patients — And Misled Congress About An HIV Pill
AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill.